Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523142 · ClinicalTrials.gov registry record · Phase 3
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
A Phase 3 study, sponsored by Novaliq.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT04523142: Completed Phase 3 study, sponsored by Novaliq.
NCT04523142 is a Phase 3 study that has completed, run by Novaliq. The registered enrollment target is 202 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04523142, a Phase 3 study, has completed, sponsored by Novaliq.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
Primary Outcome
An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not the event was considered drug related. 200 participants from the safety set were analyzed.
Interventions
- DRUG CyclASol Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2022-05-23 |
| Phase | Phase 3 |
What the finished NCT04523142 record still lists
NCT04523142 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which CyclASol Ophthalmic Solution is the first listed.
NCT04523142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04523142 about?
NCT04523142 is a clinical study titled "CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004". The objective of this trial is to evaluate safety and tolerability of CyclASol during long-term use in subjects with Dry Eye Disease.
What is the current status of trial NCT04523142?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2021-01-04. Estimated completion is 2022-05-23.
What interventions are being tested in trial NCT04523142?
The interventions under investigation include: CyclASol Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04523142?
This trial is sponsored by Novaliq, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04523142's enrollment target sits among peer trials
202 1353rd of 2000 higher than 648 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI